• Eriko Ishikawa, Hisashi Sugimoto, Miyako Hatano, Yosuke Nakanishi, Akira Tsuji, Kazuhira Endo, Satoru Kondo, Naohiro Wakisaka, Shigeyuki Murono, Makoto Ito, and Tomokazu Yoshizaki.
• Otolaryngology-Head and Neck Surgery, Toyama Prefectural Hospital , Toyama.
• Acta Otolaryngol. 2015 Sep 1; 135 (9): 919-24.

ConclusionsIntra-arterial high-dose cisplatin chemoradiation (CRT-IA) with sodium thiosulfate (STS) causes relatively less severe cisplatin ototoxicity than intravenous cisplatin chemoradiation without STS (CRT-IV). The results of this study also suggest that early detection of ototoxicity is possible by testing the hearing loss at ultra-high frequencies.ObjectivesTo investigate protective effects of STS against cisplatin ototoxicity.MethodsBetween 2011 and 2013, 18 patients with head and neck carcinomas were treated with intra-arterial infusions of high-dose cisplatin (range 100-180 mg/body, mean 111 mg/body; range 2-5 courses, mean 3.6 courses) and systemic administration of cisplatin (range 66-185 mg/body, mean 130 mg/body; range 1-3 courses, mean 2.6 courses) and concurrent radiation therapy (range 60-70 Gy, mean 69 Gy). Cisplatin was neutralized by STS in CRT-IA but not in CRT-IV.ResultsIntra-arterial infusion in the high-dose cisplatin group caused significant hearing loss at ultra-high frequencies of 10 and 12 kHz (p = 0.028, 0.039, respectively), whereas the group receiving systemic administration of cisplatin had significant hearing loss at high frequencies of 8 and 10 kHz (p = 0.016, 0.027, respectively).

36 keywords...

hide…